Josep M Llovet - Biography#

Josep M Llovet, MD, PhD is Full Prof of Medicine-Hepatic Oncology at the Univ. of Barcelona, ICREA Research Prof at IDIBAPS-Hospital Clínic Barcelona and Full Professor of Medicine and Director of the Liver Cancer Program at Icahn School of Medicine at Mount Sinai (New York). I have published 404 manuscripts (h-index:150, citations:141,268), and have been awarded by Clarivate Analytics as a top 1% cited investigator in all years from 2014 to 2025.

My research has been focused on clinical and translational studies in liver cancer for the last 30 years, with the following achievements:

• World’s most cited investigator in the area of liver cancer: Scopus: ~141,268 citations (Scopus) >168,486 (Google scholar), h-index: 162 and top 1% Clarivate analytics every year since 2014-2025. Top 0.5% Stanford investigator (# 672 globally among all disciplines, #3 in Spain)
  

• Leading author / Principal investigator of RCT, leading to practice-changing standard of care therapies.
  A) Systemic treatment (sorafenib) for hepatocellular carcinoma (HCC) (NEJM 2008), and first approved drug ever for patients with advanced tumors, 2008.
  B) First author of the clinical trial and meta-analysis establishing chemoembolization (TACE) as the standard of care for intermediate HCC (Lancet 2003).
  C) LEAP012 - Combination of lenvatinib plus pembrolizumab plus TACE, in intermediate HCC, 2024 (Lancet 2025).
  

• Leading author/Principal investigator of the proposals of molecular and immune classification of HCC (2008, 2017,NRCO 2022 and 2024).
  

• Establishment of an imaging criteria for assessment of response to therapies (modified RECIST) accepted by guidelines.
  

• Founder, Secretary and President of the International Liver Cancer Association (ILCA), the only international scientific society devoted to liver cancer (2006-2013).
  

• Founder and Director of the Mount Sinai Liver Cancer Program (2005-2023), the first liver cancer program recognized by NCI in the USA.
  

• Principal investigator of research funding with 104 awards as PI, including coordinator of 2 European Union FP7 and Horizon Europe grants (HEPTROMIC and THRIVE) and 2 NIH-RO1 and the AECC-Reto 70% award, with an total of ~56M€ as PI